Lindbrook Capital’s Immunic IMUX Stock Holding History

Lindbrook Capital’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-420	Closed	-$64K	–	1900
2020 Q4	$64K	Hold	420	–	–	0.02%	341
2020 Q3	$78K	Buy	+420	New	+$68.8K	0.02%	255

Other funds holding IMUX

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's IMUX Position: Q1 2021 in Review

Lindbrook Capital sold out of Immunic (IMUX) in Q1 2021, closing a stake of 420 shares — an estimated $64K sold.

Lindbrook Capital first reported a position in IMUX in Q3 2020 and held it in 2 quarters. The position peaked at $78K in Q3 2020. 63 funds tracked by Wall St. Rank hold IMUX as of Q1 2021.

Lindbrook Capital reported no remaining Immunic position as of Q1 2021 after selling out during the quarter.
Lindbrook Capital sold 420 Immunic shares in Q1 2021, an estimated $64K.
Lindbrook Capital first reported a position in Immunic in Q3 2020 and held it in 2 quarters.
Lindbrook Capital's Immunic position peaked at $78K in Q3 2020.
63 funds tracked by Wall St. Rank held Immunic as of Q1 2021.

Based on Lindbrook Capital's 13F filing for Q1 2021, filed 28 Apr 2021.